67 Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer

Títulos similares

• Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
  por: Lauren Jones, et al.
  Publicado: (2022-11-01)
• Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia
  por: Filip Marković, et al.
  Publicado: (2025-05-01)
• Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
  por: Biagio Ricciuti, MD, PhD, et al.
  Publicado: (2024-09-01)
• Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
  por: Elizabeth Dudnik, et al.
  Publicado: (2021-01-01)
• Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50%
  por: Mario Occhipinti, et al.
  Publicado: (2026-03-01)